ORIC:NASDAQOric Pharmaceuticals, Inc. analysis
Data as of Oct 14, 2026 - not real-time
- Latest price
- $11.51
- Risk: high
- 9/10High risk
Summary
ORIC Pharmaceuticals, Inc. trades at $11.51, with its moving averages tangled rather than clearly stacked — a neutral trend structure. Across the trailing 30 sessions it lost 10.7%. RSI sits at 36.8, which reads as approaching oversold, and MACD momentum is bearish. The recent range runs from support at $10.93 up to resistance at $14.12.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 86.2% above the current quote.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 43.6%, a beta of 1.32 and a maximum drawdown of 46.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
All three time horizons resolve to hold, carrying 2/10 conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 86.2% above the current quote.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 43.6%, a beta of 1.32 and a maximum drawdown of 46.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
All three time horizons resolve to hold, carrying 2/10 conviction.
Top market events
- On August 3, ORIC Pharmaceuticals NASDAQ:ORIC reported second-quarter results that showed a clinical-stage biotech...
- SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 02, 2026 GLOBE NEWSWIRE -- ORIC Pharmaceuticals, Inc. Nasdaq: ORIC , a...
- ORIC Pharmaceuticals stock stood at USD 13.
Market outlook
Short term
< 1 yearNeutral
Model confidence2/102 out of 10
Key factors
- Trading above the 200-day average of 10.98
- MACD momentum is negative
- 30-day price change of -10.7%
Medium term
1–3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Trading above the 200-day average of 10.98
- Analyst targets imply +86.2% versus the current price
- 30-day volatility of 43.6%
Long term
> 3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Analyst targets imply +86.2% versus the current price
- Negative return on equity of -39.8%
- Negative free cash flow
Key metrics
Financial health
P/E Ratio-6.9
ROE-39.80%
ROA-25.97%
Debt/Equity1.57
P/B Ratio3.1
Op. Cash Flow$-111638000
Free Cash Flow$-68834624
Industry P/E30.9
Technical analysis
TrendNeutral
RSI36.8
Support$10.93
Resistance$14.12
MA 20$12.57
MA 50$12.98
MA 200$10.98
MACDBearish
VolumeDecreasing
Fear & Greed Index93
Valuation
Target Price$21.43
Upside/Downside86.17%
GradeFair
TypeBlend
Risk assessment
Beta1.32
Volatility43.55%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.